Showing results (161-170 of 211) with videos related to

Sort By:
Pageof 22
Diabetes Care|October 22, 2008
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetesChiara Dalla Man, Gerlies Bock, Paula D Giesler, et al.
The Journal of Clinical Investigation|September 26, 2023
Glucagon-like peptide-1 receptor blockade impairs islet secretion and glucose metabolism in humansAndrew A Welch, Rahele A Farahani, Aoife M Egan, et al.
The Journal of Nutrition|February 4, 2015
Cholecalciferol supplementation does not influence β-cell function and insulin action in obese adolescents: a prospective double-blind randomized trialAsma Javed, Adrian Vella, P Babu Balagopal, et al.
The Journal of Clinical Endocrinology and Metabolism|September 8, 2016
Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in HumansRon T Varghese, Chiara Dalla Man, Anu Sharma, et al.
American Journal of Physiology. Endocrinology and Metabolism|February 27, 2019
Assessment of pulsatile insulin secretion derived from peripheral plasma C-peptide concentrations by nonparametric stochastic deconvolutionMarcello C Laurenti, Adrian Vella, Ron T Varghese, et al.
Clinical Endocrinology|December 31, 2009
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucoseGerlies Bock, Chiara Dalla Man, Francesco Micheletto, et al.
Diabetes|April 23, 2015
Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric BypassKim T Nguyen, Charles J Billington, Adrian Vella, et al.
The Journal of Nutrition|August 7, 2015
Six and 12 Weeks of Caloric Restriction Increases β Cell Function and Lowers Fasting and Postprandial Glucose Concentrations in People with Type 2 DiabetesMatheni Sathananthan, Meera Shah, Kim L Edens, et al.
Basic & Clinical Pharmacology & Toxicology|February 27, 2024
Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetesJens Hohwü Voigt, Katrine M Lauritsen, Steen Bønløkke Pedersen, et al.
The Journal of Surgical Research|October 15, 2023
Ethanol Ablation for Benign Insulinoma: Intraoperative and Endoscopic ApproachesAlaa Sada, Dhanya Ramachandran, Meher Oberoi, et al.
Pageof 22